Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267786 | 0.86 | ENPP2 (0.42) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL22904089 | 0.82 | ENPP2 (0.50) | ENPP2CA2CA1SNCA | |
| SCHEMBL27207998 | 0.79 | ENPP2 (0.37) | LPLLIPGENPP2 | |
| SCHEMBL29346246 | 0.77 | BLM (0.40) | ENPP2 | |
| SCHEMBL3790779 | 0.77 | LPL (0.52) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL15156401 | 0.77 | ENPP2 (0.52) | ENPP2CA2CA1 | |
| SCHEMBL14417362 | 0.76 | AR (0.42) | CA2SNCA | |
| SCHEMBL585744 | 0.76 | ENPP2 (0.47) | LPLLIPGENPP2CA2CA1 | |
| SCHEMBL8216484 | 0.75 | XDH (0.43) | ENPP2 | |
| SCHEMBL11020423 | 0.73 | CYP2A6 (0.48) | RORCSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799779-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-1863802-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1987834-A2 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1863802-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103273-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | REN, AGTR1, ACE | LPL 1476/4885LIPG 1235/4885ENPP2 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.